<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785757</url>
  </required_header>
  <id_info>
    <org_study_id>2012.788</org_study_id>
    <secondary_id>2013-A00065-40</secondary_id>
    <nct_id>NCT02785757</nct_id>
  </id_info>
  <brief_title>Cancer-related Thromboembolic Disease</brief_title>
  <acronym>PROSPECT</acronym>
  <official_title>The Challenge of Cancer-related Thromboembolic Disease: Can we Better Predict the Risk?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with cancer are at particularly high risk of venous thromboembolism (VTE). The&#xD;
      guidelines therefore strongly recommend thromboprophylaxis but recent surveys clearly show&#xD;
      that oncologists are reluctant to use it because of concern over bleeding, absence of&#xD;
      validated risk stratification tools and uncertainties concerning the optimal&#xD;
      thromboprophylaxis. Hence, it is a real challenge to identify the individual VTE risk of each&#xD;
      cancer patient and individually tailor their thromboprophylaxis.&#xD;
&#xD;
      The study aims to identify thrombin generation test (TGT) as a reliable, standardized overall&#xD;
      haemostasis assay that can be used to evaluate individual thrombosis risk&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To define the limits of TGT parameters that indicate thrombosis risk in cancer patients&#xD;
&#xD;
        -  To evaluate values of other clotting activation markers in patients with cancer&#xD;
&#xD;
      Patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin,&#xD;
      who are scheduled for systemic chemotherapy, will be enrolled in the trial at baseline (Visit&#xD;
      1). Thrombin generating capacity will be measured within the first month following diagnosis&#xD;
      and before the start of the chemotherapy (between Visit 1 and Visit 2) and subsequently at&#xD;
      the end of the first cure line of chemotherapy (Visit 3). Patients will be followed up for a&#xD;
      period of 1 year, or until the occurrence of a thromboembolic event. Two follow up visits are&#xD;
      foreseen - 6-month (Visit 4) and 12-month (or at the end of trial - Visit 5) visits.&#xD;
&#xD;
      Patients eventually undergoing second-line chemotherapy during the course of the follow-up&#xD;
      will remain on study.&#xD;
&#xD;
      The study will document all cases of symptomatic thromboembolic events together with the&#xD;
      relevant diagnostic work-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2014</start_date>
  <completion_date type="Anticipated">February 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>thrombin generation assay results</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clotting activation markers: thrombin-antithrombin complexes (TAT)</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clotting activation markers: prothrombin fragment F1+2</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clotting activation markers: D-dimer</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Patients with adenocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 Patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Thrombin Generation Assay</intervention_name>
    <arm_group_label>Patients with adenocarcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients of both sexes with locally advanced or metastatic adenocarcinoma of any&#xD;
             origin, who are scheduled for systemic chemotherapy&#xD;
&#xD;
          -  Subjects having signed Informed Consent prior to initiation of any study procedure&#xD;
&#xD;
          -  Covered by a Health System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known bleeding or thrombophilia disorders&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3&#xD;
&#xD;
          -  Patient immobilized&#xD;
&#xD;
          -  Confirmed venous thromboembolism in the last 12 months&#xD;
&#xD;
          -  Active bleeding or bleedings in the last 4 weeks requiring hospitalization,&#xD;
             transfusion, or surgical intervention&#xD;
&#xD;
          -  Anticoagulant therapy at the moment of first sampling (at least one day off for&#xD;
             Heparines and DOAc; at least 5 days off for VKA is needed)&#xD;
&#xD;
          -  Antiplatelet therapy at the moment of first sampling (only if PRP TGA can be performed&#xD;
             at site)&#xD;
&#xD;
          -  Severe hepatic insufficiency&#xD;
&#xD;
          -  Life expectancy of less than 3 months&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yesim DARGAUD, MD PHD</last_name>
    <phone>(0)4 72 11 88 25</phone>
    <phone_ext>+33</phone_ext>
    <email>ydargaud@univ-lyon1.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unité d'Hémostase Clinique Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesim Dargaud, MD, PhD</last_name>
      <phone>(0)4 72 11 88 25</phone>
      <phone_ext>+33</phone_ext>
      <email>ydargaud@univ-lyon1.fr</email>
    </contact>
    <investigator>
      <last_name>Yesim Dargaud, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>thrombin generation assay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

